Clovis Oncology names CMO
This article was originally published in Scrip
Clovis Oncology has named Dr Lindsey Rolfe chief medical officer and executive vice-president of clinical and preclinical development and pharmacovigilance – effective from early August. Dr Rolfe succeeds Dr Andrew Allen, who will be stepping down from his role at Clovis to create a new immuno-oncology focused biotechnology company and serve as its CEO. Dr Rolfe joined Clovis in early 2010 and oversees rociletinib and rucaparib development in her current role as senior vice-president of clinical development.